Article Page

Abstract

Quantum key distribution is a technique to securely distribute a bit string between two parties by using the laws of quantum mechanics. The security of this technique depends on the basis of quantum mechanics rather than the difficulty of the mathematical calculation as in the classical encoding. Researches in this field have shown that the quantum key distribution will be fully func-tioning outside the laboratory in a few years. Due to the complexity and the high efficiency of the device, the verification is needed. In this article, we use PRISM to verify the security of the quan-tum key distribution protocol, which uses the entangled photon based on BB84 in silico Model Checking Development of a Synthetic Gp 46-gp21 derived P400-P197 Peptide mimetic pharmacophore as a potential HTLV-1 Fusion Inhibitor in a mass-action law based new cluster of algorithms protocol

Keywords

Analysis of Security; Quantum Key; Distribution Based; Entangled Photon Pairs; Model Checking; in silico Development; Synthetic Gp 46-gp21; P400-P197 Peptide mimetic; pharmacophore; HTLV-1 Fusion Inhibitor; mass-action law; new cluster of algorithms;Cryptography, Quantum Cryptography, Quantum Key Distribution, Model Checking

Article Type

Research Article – Abstract

Publication history

Received: Sep 20, 2017
Accepted: Sep 25, 2017
Published: Oct 01, 2017

Citation

Grigoriadis Ioannis, Grigoriadis George, Grigoriadis Nikolaos, George Galazios (2017) Analysis of Security of Quantum Key Distribution Based on Entangled Photon Pairs by in silico Model Checking Development of a Synthetic Gp 46-gp21 derived P400-P197 Peptide mimetic pharmacophore as a potential HTLV-1 Fusion Inhibitor in a mass-action law based new cluster of algorithms

Authors Info

Grigoriadis Nikolaos
Department of IT Computer Aided Personalized Myoncotherapy, Cartigenea-Cardiogenea, Neurogenea-Cellgenea, Cordigenea-HyperoligandorolTM,
Biogenea Pharmaceuticals Ltd,
Thessaloniki, Greece;

Grigoriadis Ioannis
Department of Computer Drug Discovery Science, BiogenetoligandorolTM,
Biogenea Pharmaceuticals Ltd,
Thessaloniki, Greece;

Grigoriadis George
Department of Stem Cell Bank and ViroGeneaTM,
Biogenea Pharmaceuticals Ltd,
Thessaloniki, Greece;

George Galazios
Professor of Obstetrics and Gynecology,
Democritus University of Thrace,
Komotini, Greece;

E-mail: biogeneadrug@gmail.com

File not available